- Home
- PVL vs ATNM Comparison
PVL vs ATNM Comparison
Compare PVL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- ATNM
- Stock Information
- Founded
- PVL 2011
- ATNM 2000
- Country
- PVL United States
- ATNM United States
- Employees
- PVL N/A
- ATNM N/A
- Industry
- PVL Oil & Gas Production
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- PVL Energy
- ATNM Health Care
- Exchange
- PVL Nasdaq
- ATNM Nasdaq
- Market Cap
- PVL 57.8M
- ATNM 50.2M
- IPO Year
- PVL N/A
- ATNM N/A
- Fundamental
- Price
- PVL $1.79
- ATNM $1.41
- Analyst Decision
- PVL
- ATNM Strong Buy
- Analyst Count
- PVL 0
- ATNM 1
- Target Price
- PVL N/A
- ATNM $4.00
- AVG Volume (30 Days)
- PVL 82.4K
- ATNM 211.4K
- Earning Date
- PVL 01-01-0001
- ATNM 11-14-2025
- Dividend Yield
- PVL 19.89%
- ATNM N/A
- EPS Growth
- PVL N/A
- ATNM N/A
- EPS
- PVL 0.06
- ATNM N/A
- Revenue
- PVL $3,511,891.00
- ATNM $90,000.00
- Revenue This Year
- PVL N/A
- ATNM N/A
- Revenue Next Year
- PVL N/A
- ATNM N/A
- P/E Ratio
- PVL $27.17
- ATNM N/A
- Revenue Growth
- PVL 11.77
- ATNM 11.11
- 52 Week Low
- PVL $1.30
- ATNM $1.03
- 52 Week High
- PVL $2.04
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- PVL 51.08
- ATNM 54.09
- Support Level
- PVL $1.76
- ATNM $1.25
- Resistance Level
- PVL $1.86
- ATNM $1.42
- Average True Range (ATR)
- PVL 0.06
- ATNM 0.10
- MACD
- PVL -0.00
- ATNM 0.02
- Stochastic Oscillator
- PVL 53.85
- ATNM 59.46
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.